EQL PHARMA AB

Research EQL PHARMA AB (7JK) on Bullrun: market cap EUR 52.68M, P/E 44.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 52.68M; P/E is 44.6.

Peer valuation comparison

Latest P/E is 44.6x versus a Healthcare sector median of 23.83x (87.2% above).

Latest P/E is 44.6x versus a Sweden median of 18.63x (139.4% above).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-07-29EUR 52.68M44.6n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About EQL PHARMA AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

Related stock research

Sweden stocks Sweden Healthcare stocks A-Z stock index

Other Healthcare stocks

PEPTONIC MEDICAL (28L) CERENO SCIENTIFIC AB B (4A1) KLARIA PHARMA HOLDING AB (6FN) ODI PHARMA AB (6OD) BioGaia AB (publ) (BIOG-B) Cinclus Pharma (CINPHA) Cereno Scientific AB Series B (CRNO-B) Dicot AB (DICOT) Enzymatica publ AB (ENZY) Enorama Pharma AB (ERMA) Gabather AB (publ) (GABA) Moberg Pharma AB (publ) (MB8)

Frequently asked questions

What is EQL PHARMA AB's market cap?

EQL PHARMA AB's market capitalization is EUR 52.68M.

What is EQL PHARMA AB's P/E ratio?

EQL PHARMA AB's price-to-earnings (P/E) ratio is 44.6.

What does EQL PHARMA AB do?

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.